Clinical Trials Logo

Chronic Bronchitis clinical trials

View clinical trials related to Chronic Bronchitis.

Filter by:

NCT ID: NCT03893370 Active, not recruiting - Chronic Bronchitis Clinical Trials

RejuvenAir® System Trial for COPD With Chronic Bronchitis

SPRAY-CB
Start date: July 9, 2020
Phase: N/A
Study type: Interventional

Chronic Obstructive Pulmonary Disease (COPD) is defined as an impaired ability to move air within the lungs and is a major public health problem that is projected to rank fifth worldwide in terms of disease burden and third in terms of mortality. Chronic bronchitis (CB) is a common clinical phenotype within the umbrella of a COPD diagnosis and is classically defined as chronic cough and sputum production for 3 months a year for 2 consecutive years2, but many studies have used different definitions to define it- chronic cough and sputum production for one year or cough and sputum production on most days of the week. CB is associated with multiple clinical consequences, including; the worsening of lung function decline, increasing risk of acute exacerbations of COPD, increased risk of developing pneumonia, reduced health related quality of life, and an increase in all-cause mortality.

NCT ID: NCT03892694 Active, not recruiting - COPD Clinical Trials

Metered Cryospray for the Treatment of Patients With Chronic Obstructive Pulmonary Disease With Chronic Bronchitis

Start date: February 14, 2020
Phase: N/A
Study type: Interventional

To evaluate the relationship between airway structure and function in patients with chronic bronchitis treated with metered cryospray (MCS).

NCT ID: NCT03827590 Recruiting - Acute Bronchitis Clinical Trials

Clinical Trials to Assess the Efficacy and Safety of HLIM

Start date: November 29, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess the efficacy and safety of HLIM

NCT ID: NCT03738917 Completed - Acute Bronchitis Clinical Trials

Effectiveness of Antitussives, Anticholinergics and Honey Versus Usual Care in Adults With Acute Bronchitis.

AB4T
Start date: February 1, 2019
Phase: Phase 4
Study type: Interventional

This study, which is aimed at comparing the effectiveness of 3 symptomatic therapies (dextromethorphan, ipratropium and honey) associated with usual care and the usual care in adults with acute bronchitis, is a multicentre, pragmatic, parallel group, open randomised trial. Patients aged 18 or over with uncomplicated acute bronchitis, with cough <3 weeks as the main symptom, scoring ≥ 4 in either daytime or nocturnal cough on a 7-point Likert scale, will be randomised to one of the 4 groups. Sample: 668 patients. The primary outcome will be the number of days with moderate-severe cough.

NCT ID: NCT03711292 Completed - Acute Bronchitis Clinical Trials

Using Behavioral Science to Reduce Inappropriate Antibiotic Use in Acute Care Settings

Start date: September 7, 2018
Phase: N/A
Study type: Interventional

Stepped wedge behavioral intervention clinical trial looking at the impact of an antibiotic stewardship intervention on provider prescribing behavior for acute respiratory infections (ARIs), where the intervention is administered at the emergency department or urgent care center site level, using a cluster randomization process. Thus, every site and every provider are eligible to be exposed to the stewardship intervention, the cluster randomized stepped wedge process simply randomizes when they will be exposed. The overall study hypothesis is that providers will prescribe fewer unnecessary antibiotics to patients with ARIs after the intervention.

NCT ID: NCT03657836 Completed - Acute Bronchitis Clinical Trials

The Sublimated Mare Milk Supplement's Effect on Gut Mucosal Lining After Antibiotics

Start date: August 1, 2018
Phase: N/A
Study type: Interventional

This clinical trial studies the effect of sublimated mare milk supplement on gut microbiome of patients with acute bronchitis.

NCT ID: NCT03657121 Completed - Clinical trials for Pulmonary Disease, Chronic Obstructive

Mortality and Symptom Burden Post Hospitalisation With COPD

MoSHCOPD
Start date: January 16, 2019
Phase:
Study type: Observational

Chronic Obstructive Pulmonary Disease (COPD) is a common progressive lung disease which causes breathlessness and frequent exacerbations, with patients often requiring hospitalisation. Patients with severe COPD commonly become housebound and lose their independence. They have a higher symptom burden than those with incurable lung cancer, yet are less likely to receive specialist palliative care, or to have been engaged in advance care planning (where patients discuss and often document their wishes regarding their future care). Hospital admissions become increasingly common towards the end-of-life; therefore, hospitalisation is a good opportunity to identify patients at risk of poor outcome. Such patients may wish to consider alternatives to admission and avoid intrusive treatments. Unfortunately, predicting which patients are likely to die in the near future is challenging thus far. The first step required to improve provision of palliative care services, and ensure patients are given the opportunity to make truly informed decisions about their future care, is accurate identification of those most likely to benefit. Well-designed clinical (prognostic) tools outperform clinician judgement in most settings. The investigators will compare the accuracy of one year mortality prediction of several clinical tools in patients who survive a COPD exacerbation requiring admission. This will initially be performed using existing data collected during previous research (the 1,593 patient validation study for the PEARL score - Previous admissions, extended Medical Research Council Dyspnoea score, Age, Right and Left heart failure), then confirmed in at least 310 patients admitted uniquely and consecutively with an exacerbation of COPD. The latter group of patients will be invited to participate in a longitudinal follow-up study, assessing symptom burden, quality of life, and readmissions over one year.

NCT ID: NCT03654196 Completed - Acute Bronchitis Clinical Trials

A Clinical Trial to Evaluate the Efficacy and Safety of HL301 Versus Umkamin Tab in Acute Bronchitis Patients

Start date: March 16, 2018
Phase: Phase 3
Study type: Interventional

A Multicenter, Randomized, Double-blinded, Active-controlled, Parallel, Phase III Clinical Trial to Evaluate the Efficacy and Safety of HL301 versus Umkamin tab. in acute bronchitis patients Endpoint: BSS, The improvement and improvement rate of the tester for the treatment response, The satisfaction of the subject

NCT ID: NCT03653104 Withdrawn - Clinical trials for Chronic Obstructive Pulmonary Disease

Melodica Orchestra for Dyspnea: Safety and Feasibility Pilot

MELODY
Start date: June 12, 2018
Phase: N/A
Study type: Interventional

This project seeks to pilot-test the feasibility of using a melodica training program to teach pursed lip breathing for Veterans with chronic obstructive pulmonary disease (COPD) with moderate to severe dyspnea (shortness of breath). Dyspnea occurs commonly among COPD patients and can limit activities of daily living. Pursed lip breathing is a strategy that can improve dyspnea and exercise capacity among COPD patients. The melodica is a musical instrument that looks like a keyboard with a mouthpiece on the side. The melodica is played by exhaling through the mouthpiece while pressing the keys. The MELODY pilot project protocol has been grounded on concepts from occupational therapy; specifically, providing participants with a meaningful new activity that is enjoyable, that can be provided across a spectrum of skill levels, that can provide participants with a new sense of self, and that can improve health outcomes (i.e., dyspnea and exercise endurance).

NCT ID: NCT03631472 Active, not recruiting - Chronic Bronchitis Clinical Trials

Gala Early Feasibility Study of RheOx

Gala_EFS
Start date: July 6, 2018
Phase: N/A
Study type: Interventional

An early feasibility study (EFS) to assess the safety and clinical utility of RheOx on patients with chronic bronchitis in the United States.